[1] Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol. 2013;25:360–366.
[2] Abdel-Nasser A, Abdel-Tawab R, Abdel-Fattah M, Mahmoud J, Sammy A. The prevalence of rheumatoid arthritis in rural Egypt: A WHO-ILAR-COPCORD Study (Conference Poster). 2004.
[3] Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861-74.
[4] Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum. 2002;46: 906–12.
[5] Kawano S, Kamae I, Kogata Y, Kogata Y, Koshiba M, Kuntz KM, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146:797.
[6] Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006;103:12481–6.
[7] Ceribelli A, Satoh M, Chan EK. MicroRNAs and autoimmunity. Curr Opin Immunol. 2012;24:686–691.
[8] Bottini N, Firestein GS. Epigenetics in rheumatoid arthritis: a primer for rheumatologists. Curr Rheumatol Rep. 2013;15:372.
[9] Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA. miRNAs and related polymorphisms in rheumatoid arthritis susceptibility. Autoimmun Rev. 2012;11:636–641.
[10] Zhou Q, Haupt S, Kreuzer JT, Hammitzsch A, Proft F, Neumann C, et al. Decreased expression of miR-146a and miR-155 contributes to an abnormal Treg phenotype in patients with rheumatoid arthritis. Ann Rheum Dis. 2014;74:1265-74.
[11] Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Nakamura T. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther. 2010;12:R86.
[12] Filková M, Aradi B, Senolt L, Ospelt C, Vettori S, Mann H, et al. Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Ann Rheum Dis. 2014;73:1898-904.
[13] Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. 2008;451:1125–1129.
[14] Sun W, Shen W, Yang S, Hu F, Li H, Zhu TH. miR-223 and miR-142 attenuate hematopoietic cell proliferation and miR-223 positively regulates miR-142 through LMO2 isoforms and CEBP-B. Cell Res. 20 (2010) 1158-69.
[15] Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived PCs. Immunity. 1998;8:363-372.
[16] Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity. 2003;18:279–288.
[17] Zhao J, Guo J, Wang L, Zhou W, Zhang Z. The role of a proliferation-inducing ligand (APRIL) in the pathogenesis of rheumatoid arthritis. Scand J Rheumatol. 2014;43:462-9.
[18] Morais SA, Vilas-Boas A and Isenberg DA. B-cell survival factors in autoimmune rheumatic disorders. Therapeutic Advances in Musculoskeletal Disease. 2015;7:122-155.
[19] Treamtrakanpon W, Tantivitayakul P, Benjachat T, Somparn P, Kittikowit W, Eiam-ong S, et al. APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. Arthritis Res Ther. 2012;14:R252.
[20] Samy E, Wax S, Huard B, Hess H, and Schneider P. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. International reviews of immunology. 2017;36:3-19.
[21] Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LP, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
[22] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-8.
[23] Tayel MY, Abdel Hamid, E, Morad ZE, Rashad EAK. AB0093 Study of B-cell activation factor (BAFF) and proliferation-inducing ligand (april) in rheumatoid arthritis patients. Ann Rheum dis. 2013;71:643.
[24] Boghdadi G, El-Sokkary RH, Elewa EA, Abbas SF. APRIL Level as a Marker of Disease Activity in Treated Rheumatoid Arthritis Patients: Association with Disease Activity and Anti-CCP Antibody. Egypt J Immunol. 2015;22:31-39.
[25] Chang Y, Jia X, Sun X, Xu S, Wu Y, Zhang L, et al. APRIL promotes proliferation, secretion and invasion of fibroblast-like synoviocyte from rats with adjuvant induced arthritis. Mol Immunol. 2015;64:90-8.
[26] Muscari I, Giannitti C, Niccolini S, Fineschi I, Sebastiani GD, Prevete I, et al. THU0011 MIR-223 expression in serum and CD3+ peripheral cells of rheumatoid arthritis. Ann Rheum dis. 2013;71:157.
[27] Fulci V, Scappucci G, Sebastiani GD, Giannitti C, Franceschini D, Meloni F, et al. miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum Immunol. 2010;71:206–11.
[28] Shibuya H, Nakasa T, Adachi N, Nagata Y, Ishikawa M, Deie M, et al. Overexpression of microRNA-223 in rheumatoid arthritis synovium controls osteoclast differentiation. Mod Rheumatol. 2013;23:674-85.
[29] Ismail N, Wang Y, Dakhlallah D, Moldovan L, Agarwal K, Batte K, et al. Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood. 2013;121:984–995.
[30] Aziz F. The emerging role of miR-223 as novel potential diagnostic and therapeutic target for inflammatory disorders. Cell Immunol. 2016;303:1-6.
[31] Haneklaus M, Gerlic M, Kurowska-Stolarska M, Rainey AA, Pich D, McInnes IB, et al. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production. J Immunol. 2012;189:3795–3799.
[32] Highton J, Hessian PA, Stamp L. The rheumatoid nodule: peripheral or central to rheumatoid arthritis. Rheumatology. 2007;46:1385– 1387.
[33] Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EKL. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 2008;10:R101.
[34] Churov AV, Oleinik EK, Knip M. MicroRNAs in rheumatoid arthritis: altered expression and diagnostic potential. Autoimmun Rev. 2015;14:1029-37.
[35] Kurowska-Stolarska M, Alivernini S, Ballantine LE, Asquith DL, Millar NL, Gilchrist DS, et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci USA. 2011;108:11193–8.
[36] Katschke KJ, Rottman JB, Ruth JH, Qin S, Wu L, LaRosa G, et al. Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum. 2001;44:1022–32.
[37] Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, et al. Requirement of bic/microRNA-155 for normal immune function. Science. 2007;316:608–611.
[38] Andonian BJ, Chou CH, Ilkayeva OR, Koves TR, Connelly MA, Kraus WE, Kraus VB and Huffman KM. Plasma MicroRNAs in Established Rheumatoid Arthritis Relate to Adiposity and Altered Plasma and Skeletal Muscle Cytokine and Metabolic Profiles. Front. Immunol. 2019;10:1475.
[39] Anaparti V, Smolik I, Meng X, Spicer V, Mookherjee N, El-Gabalawy H. Whole blood microRNA expression pattern differentiates patients with rheumatoid arthritis, their seropositive first-degree relatives, and healthy unrelated control subjects. Arthritis Res Ther. 2017;19:249.